1. In Vivo

Dealmaking Quarterly Statistics, Q2 2020

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

 
• By Deanna Kamienski and Maureen Riordan

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Quarterly Stats_1200x675

Biopharma merger and acquisition value for the second quarter of 2020 reached $5.9bn, a 14% decline from Q1’s $6.9bn (see Exhibit 1). At the top (making up about a third of this total) was Novo Nordisk AS’s $2.1bn buy of private US biotech Corvidia Therapeutics [See Deal] Novo is paying $725m in cash up front and could provide earn-outs of up to $1.375bn upon the achievement of milestones tied to Corvidia's ziltivekimab, its Phase II candidate for chronic kidney disease. Also see "Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy" - Scrip, 11 June, 2020.

Exhibit 1.

More from Deal-Making

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.